Zacks: Brokerages Expect Heron Therapeutics, Inc. (NASDAQ:HRTX) to Announce -$0.45 EPS

Wall Street brokerages expect that Heron Therapeutics, Inc. (NASDAQ:HRTX – Get Rating) will post earnings per share (EPS) of ($0.45) for the current quarter, according to Zacks. Three analysts have provided estimates for Heron Therapeutics’ earnings. The lowest EPS estimate is ($0.56) and the highest is ($0.30). Heron Therapeutics posted earnings of ($0.58) per share in the same quarter last year, which would suggest a positive year over year growth rate of 22.4%. The firm is scheduled to issue its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Heron Therapeutics will report full-year earnings of ($1.59) per share for the current financial year, with EPS estimates ranging from ($2.18) to ($0.82). For the next year, analysts expect that the company will report earnings of ($0.91) per share, with EPS estimates ranging from ($1.20) to ($0.40). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX – Get Rating) last posted its quarterly earnings results on Monday, February 28th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.05. Heron Therapeutics had a negative return on equity of 159.70% and a negative net margin of 255.58%. The business had revenue of $20.66 million for the quarter, compared to the consensus estimate of $25.77 million. During the same quarter in the prior year, the company earned ($0.68) EPS. The business’s revenue was up .2% compared to the same quarter last year.

A number of equities research analysts recently weighed in on HRTX shares. Zacks Investment Research downgraded Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, February 9th. StockNews.com started coverage on Heron Therapeutics in a research report on Thursday, March 31st. They set a “sell” rating on the stock. Cowen dropped their price objective on Heron Therapeutics from $31.00 to $13.00 in a research report on Tuesday, March 1st. Cantor Fitzgerald dropped their price objective on Heron Therapeutics from $26.00 to $20.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 1st. Finally, Needham & Company LLC dropped their price objective on Heron Therapeutics from $24.00 to $16.00 in a research report on Tuesday, March 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $18.46.

Institutional investors have recently added to or reduced their stakes in the business. Zullo Investment Group Inc. purchased a new stake in Heron Therapeutics in the fourth quarter valued at about $30,000. Dark Forest Capital Management LP raised its stake in Heron Therapeutics by 3,258.7% in the third quarter. Dark Forest Capital Management LP now owns 3,090 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 2,998 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Heron Therapeutics in the third quarter valued at about $37,000. Russell Investments Group Ltd. purchased a new stake in Heron Therapeutics in the fourth quarter valued at about $39,000. Finally, Newbridge Financial Services Group Inc. purchased a new stake in Heron Therapeutics in the third quarter valued at about $73,000.

HRTX opened at $5.87 on Friday. Heron Therapeutics has a 12-month low of $4.58 and a 12-month high of $18.99. The business’s fifty day simple moving average is $6.33 and its 200-day simple moving average is $8.55. The company has a market capitalization of $599.57 million, a price-to-earnings ratio of -2.61 and a beta of 1.32. The company has a current ratio of 3.58, a quick ratio of 2.90 and a debt-to-equity ratio of 1.92.

About Heron Therapeutics (Get Rating)

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Featured Articles